Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326)

Phase Iii Study ◽

Oral Versus Intravenous Administration of Vinorelbine as a Single Agent for the First-Line Treatment of Metastatic Nonsmall Cell Lung Carcinoma (NSCLC)

American Journal of Clinical Oncology ◽

10.1097/01.coc.0000256103.21797.e5 ◽

2007 ◽

Vol 30 (3) ◽

pp. 245-251 ◽

Cited By ~ 14

Author(s):

Vera Hirsh ◽

Pierre Desjardins ◽

Burton M. Needles ◽

James R. Rigas ◽

Mohammad Jahanzeb ◽

...

Keyword(s):

Lung Carcinoma ◽

Intravenous Administration ◽

Single Agent ◽

Line Treatment ◽

First Line ◽

Cell Lung Carcinoma ◽

First-line treatment of advanced nonsmall cell lung carcinoma with docetaxel and vinorelbine

Cancer ◽

10.1002/(sici)1097-0142(19981115)83:10<2083::aid-cncr6>3.0.co;2-i ◽

1998 ◽

Vol 83 (10) ◽

pp. 2083-2090 ◽

Cited By ~ 38

Author(s):

Charalambos Kourousis ◽

Nicos Androulakis ◽

Stelios Kakolyris ◽

John Souglakos ◽

George Maltezakis ◽

...

Keyword(s):

Lung Carcinoma ◽

Line Treatment ◽

First Line ◽

Cell Lung Carcinoma ◽

Phase II study of paclitaxel and epirubicin as first-line treatment in patients with metastatic nonsmall cell lung carcinoma

Cancer ◽

10.1002/1097-0142(20000701)89:1<89::aid-cncr13>3.0.co;2-z ◽

2000 ◽

Vol 89 (1) ◽

pp. 89-96 ◽

Cited By ~ 4

Author(s):

Giovanni L. Ceresoli ◽

Stefania Dell'Oro ◽

Paolo Passoni ◽

Eugenio Villa

Keyword(s):

Phase Ii ◽

Lung Carcinoma ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Cell Lung Carcinoma ◽

A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLC

Case Medical Research ◽

10.31525/ct1-nct04033354 ◽

2019 ◽

Author(s):

Keyword(s):

Stage Iiib ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

Phase Iii Study ◽

Faculty Opinions recommendation of Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958548.793464802 ◽

2012 ◽

Author(s):

Yiqian Nancy You ◽

Brian Keith Bednarski

Keyword(s):

Colorectal Cancer ◽

Advanced Colorectal Cancer ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Phase Iii Study ◽

Randomized phase III trial of avelumab + axitinib vs sunitinib as first-line treatment for advanced renal cell carcinoma: JAVELIN renal 101 Japanese subgroup analysis

Annals of Oncology ◽

10.1093/annonc/mdz249.052 ◽

2019 ◽

Vol 30 ◽

pp. v386-v387

Author(s):

M. Uemura ◽

Y. Tomita ◽

H. Miyake ◽

S. Hatakeyama ◽

H.-O. Kanayama ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Subgroup Analysis ◽

Renal Cell ◽

Phase Iii ◽

Advanced Renal Cell Carcinoma ◽

Line Treatment ◽

First Line ◽

Phase Iii Trial ◽

Phase III study of watchful waiting vs. rituximab as first-line treatment in advanced stage follicular lymphoma with low tumour burden (JCOG1411, FLORA study)

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyy085 ◽

2018 ◽

Vol 48 (8) ◽

pp. 777-780 ◽

Cited By ~ 2

Author(s):

Kenichi Miyamoto ◽

Noriko Fukuhara ◽

Dai Maruyama ◽

Taro Shibata ◽

Kenichi Nakamura ◽

...

Keyword(s):

Follicular Lymphoma ◽

Watchful Waiting ◽

Phase Iii ◽

Advanced Stage ◽

Line Treatment ◽

Tumour Burden ◽

First Line ◽

Phase Iii Study ◽

Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)

Gastric Cancer ◽

10.1007/s10120-011-0009-5 ◽

2011 ◽

Vol 14 (1) ◽

pp. 72-80 ◽

Cited By ~ 97

Author(s):

Hiroyuki Narahara ◽

Hiroyasu Iishi ◽

Hiroshi Imamura ◽

Akira Tsuburaya ◽

Keisho Chin ◽

...

Keyword(s):

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Iii ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Cancer Study ◽

Gastric Cancer Study ◽

Phase Iii Study ◽

Global phase III study of tislelizumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma (HCC): A trial-in-progress

Annals of Oncology ◽

10.1093/annonc/mdy282.159 ◽

2018 ◽

Vol 29 ◽

pp. viii264-viii265

Author(s):

S. Qin ◽

R.S. Finn ◽

M. Kudo ◽

T. Meyer ◽

A. Vogel ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Phase Iii ◽

Advanced Hepatocellular Carcinoma ◽

Line Treatment ◽

First Line ◽

Phase Iii Study ◽

Abstract CT211: ORIENT-15: A randomized, multicenter, double-blind, Phase III study of sintilimab + paclitaxel and cisplatin (TP) versus placebo + TP as first-line treatment in patients with unresectable locally advanced or metastatic esophageal squamous cell carcinoma

10.1158/1538-7445.am2019-ct211 ◽

2019 ◽

Author(s):

Lin Shen ◽

Zhihao Lu ◽

Linxinyu Xu ◽

Yan Wang ◽

Hui Zhou ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Locally Advanced ◽

Phase Iii ◽

Line Treatment ◽

First Line ◽

Double Blind ◽

Phase Iii Study ◽